Trial details
qBOLD MRI of Glioblastoma Multiforme for Assessment of Tumor Hypoxia
To find out more about this trial and your cancer treatment options, please speak with your doctor.
Trial short name: qBOLD in MRI
Official title: qBOLD MRI of Glioblastoma Multiforme for Assessment of Tumor Hypoxia
Principal Investigator: Dr. Pejman Jabehdar Maralani
Cancer type: Central Nervous System
Cancer location: Brain
Disease stage: Early and Advanced Cancer
Trial phase: Other
Intervention: Drug: Ferumoxytol
Registration #:
NCT02466828 
Contact e-mail: cancerclinicaltrials@sunnybrook.ca
Trial description:
The purpose of this study is to evaluate the effectiveness of a new magnetic resonance imaging (MRI) technique to measure oxygen levels in glioblastoma multiforme (GBM) tumors. Patients with newly diagnosed GBM who are to have surgical treatment and chemotherapy may be able to participate. All patients participating in the study will receive ferumoxytol (a MRI contrast agent) before having an MRI scan. By determining oxygen levels within GBMs, doctors may be better able to plan treatment for patients.
Inclusion Criteria: • Adult (>18 year old) patients with newly diagnosed GBM presenting to our centre for surgical management and post-operative chemoradiation • Creatinine clearance > 60 ml/minute • Able to tolerate an MR scan • Capable of providing informed consent. Exclusion Criteria: • Prior brain surgery or radiation • History of liver disease requiring liver MRI (due to accumulation of ferumoxytol in Kupffer cells which can affect liver MRI for up to 3 months) • On more than two antihypertensive medications • History of allergy or adverse reaction to iron supplements • Prior treatment with ferumoxytol • Large (>50%) hemorrhagic component in the solid enhancing part of the tumor • Need for emergency craniotomy. • Pregnant patients • Breast feeding • Serum ferritin of >800 ng/mL
